Patent · US Active

Anti-sortilin antibodies and methods of use thereof

US10087255B2 · kind B2 · utility

10Cited by

41References

17Claims

0Family size

Assignee

Alector LLC

Inventors

Arnon Rosenthal · Woodside, US
Tina SCHWABE · San Francisco, US
Michael Kurnellas · San Francisco, US

Key dates

Filing date	Oct 4, 2016
Grant date	Oct 2, 2018
Priority date	—
Expiry date	Oct 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.